Buy Ipamorelin for Research: Complete Guide to CJC-1295 Blend

What Is Ipamorelin?

Ipamorelin is a pentapeptide growth hormone secretagogue (Aib-His-D-2Nal-D-Phe-Lys-NH2) developed by Novo Nordisk that selectively activates the ghrelin receptor (GHS-R1a) to stimulate pituitary growth hormone release. It is distinguished from older growth hormone releasing peptides (GHRPs) by its high receptor selectivity — producing GH secretion with minimal stimulation of prolactin, cortisol, or ACTH, making it particularly valuable for research protocols requiring clean GH stimulation without confounding hormonal effects.

Search volume for “ipamorelin peptide for sale” has grown consistently, reflecting its position as one of the most used GH secretagogues in research settings. Its combination with CJC-1295 (a GHRH analog) represents a well-established synergistic research protocol documented across numerous published studies.

Mechanism of Action

• GHS-R1a Agonism: Binds and activates the ghrelin receptor on anterior pituitary somatotrophs, triggering GH synthesis and secretion
• GH Pulsatility Preservation: Stimulates GH in a pulsatile pattern consistent with physiological secretion — a key advantage over continuous GH infusion models
• Prolactin Sparing: Negligible prolactin stimulation compared to GHRP-2 and GHRP-6 at equivalent GH-releasing doses
• Cortisol Sparing: No meaningful HPA axis activation, distinguishing it from non-selective GHRPs
• GHRH Synergy: When co-administered with GHRH analogs (e.g., CJC-1295), GH response is amplified 5–10× over either compound alone — dual pathway stimulation (GHRHR + GHS-R1a)

Research Data

GH Secretion Studies

• Dose-dependent GH elevation: 1–10 µg/kg doses produce 2–10× baseline GH in rodent models
• Peak GH response at 15–30 minutes post-administration, return to baseline by 3 hours
• No tachyphylaxis (receptor desensitization) observed with twice-daily dosing in 28-day rodent studies

Body Composition and Anabolic Research

• Increased lean body mass and reduced fat mass in 8-week rodent studies at 100 µg/kg twice daily
• Improved muscle protein synthesis markers and reduced catabolic gene expression in aged rodent muscle
• Enhanced bone mineral density in aged ovariectomized rat models — implying utility in osteoporosis research

Ipamorelin + CJC-1295 Combination Research

The combination is one of the most studied in GH secretagogue research:

• Synergistic effect: CJC-1295 increases GH pulse amplitude via GHRHR; ipamorelin amplifies pulse frequency via GHS-R1a
• Combined administration produces GH responses 5–10× greater than either compound alone in rodent models
• IGF-1 levels sustained above baseline for 12–24 hours with combination vs. 3–4 hours for ipamorelin alone
• Pre-mixed CJC-1295 No DAC / Ipamorelin blends simplify research protocols requiring both compounds

Dosage Reference for Research

Research reference only. Not dosing guidance for human use.

Ipamorelin vs. Other GH Secretagogues

Where to Buy Ipamorelin for Research

Quality criteria for ipamorelin sourcing:

• HPLC purity ≥99% with sequence-confirmed COA
• MS/MS confirmation of pentapeptide identity
• Sterility testing for in vivo protocols
• Blend options: pre-mixed CJC-1295/ipamorelin for combination study convenience

HPLC Verified

Ipamorelin 10mg

Purity: 99%+ HPLC

Format: Lyophilized Powder

Testing: Third-Party COA

$85

Buy Now

HPLC Verified

Ipamorelin / CJC-1295 No DAC 10mg

Purity: 99%+ HPLC

Blend: 10mg combo vial

Testing: Third-Party COA

$120

Buy Now

HPLC Verified

Ipamorelin / CJC-1295 12mg/6mg

Purity: 99%+ HPLC

Blend: 12mg/6mg ratio

Testing: Third-Party COA

$160

Buy Now

Research Disclaimer: This product is sold strictly for in vitro research and laboratory use only. Not for human consumption. Not medical advice.